Fusion Pharmaceuticals is a triple, says Raymond James – Cantech Letter

Raymond James analyst Rahul Sarugaser initiated coverage with an “Outperform” rating on Friday on Fusion Pharmaceuticals.

Related Keywords

Boston ,Massachusetts ,United States ,Novarti Pluvicto ,Rahul Sarugaser ,Novarti Lutathera ,Bayer Xofigo ,Fusion Pharmaceuticals Stock ,Fusion Pharmaceuticals ,Astrazeneca ,Fusion Pharmaceuticals Stock Quote ,Raymond James ,Analyst Rahul Sarugaser ,